Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings
Abstract Patients with breast cancer frequently experience financial hardship, often due to the high costs of anti-cancer drugs. We sought to develop alternative trastuzumab dosing strategies, compare their pharmacokinetic effectiveness to standard dosing, and assess the expected financial implicati...
Main Authors: | Po-Hung Hsieh, Alec J. Kacew, Marie Dreyer, Anthony V. Serritella, Randall W. Knoebel, Garth W. Strohbehn, Mark J. Ratain |
---|---|
Format: | Article |
Language: | English |
Published: |
Nature Portfolio
2022-03-01
|
Series: | npj Breast Cancer |
Online Access: | https://doi.org/10.1038/s41523-022-00393-2 |
Similar Items
-
Quantification of Trastuzumab–HER2 Engagement In Vitro and In Vivo
by: Alena Rudkouskaya, et al.
Published: (2020-12-01) -
In-Trastuzumab Scintigraphy in HER2-Positive Metastatic Breast Cancer Patients Remains Feasible during Trastuzumab Treatment
by: Sietske B.M. Gaykema, et al.
Published: (2014-07-01) -
Distribution and Determinants of Out-of-pocket Healthcare Expenditures in Bangladesh
by: Rashidul Alam Mahumud, et al.
Published: (2017-03-01) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
by: Jamunarani Veeraraghavan, et al.
Published: (2021-05-01) -
Termination of trastuzumab in HER2-positive metastatic breast cancer patients who received trastuzumab beyond progression
by: Izzet Dogan, et al.
Published: (2023-05-01)